Author:
Yunchu Yang,Miyanaga Akihiko,Matsuda Kuniko,Kamio Koichiro,Seike Masahiro
Abstract
AbstractSmall cell lung cancer (SCLC) is well known as a highly malignant neuroendocrine tumor. Immunotherapy combined with chemotherapy has become a standard treatment for extensive SCLC. However, since most patients quickly develop resistance and relapse, finding new therapeutic targets for SCLC is important. We obtained four microarray datasets from the Gene Expression Omnibus database and screened differentially expressed genes by two methods: batch correction and “RobustRankAggregation”. After the establishment of a protein–protein interaction network through Cytoscape, seven hub genes (AURKB, BIRC5, TOP2A, TYMS, PCNA, UBE2C, and AURKA) with high expression in SCLC samples were obtained by eight CytoHubba algorithms. The Least Absolute Shrinkage and Selection Operator regression and the Wilcoxon test were used to analyze the differences in the immune cells’ infiltration between normal and SCLC samples. The contents of seven kinds of immune cells were considered to differ significantly between SCLC samples and normal samples. A negative association was found between BIRC5 and monocytes in the correlation analysis between immune cells and the seven hub genes. The subsequent in vitro validation of experimental results showed that downregulating the expression of BIRC5 by siRNA can promote apoptotic activity of SCLC cells and inhibit their vitality, migration, and invasion. The use of BIRC5 inhibitor inhibited the vitality of SCLC cells and increased their apoptotic activity. BIRC5 may be a novel therapeutic target option for SCLC.
Funder
the Ministry of Education, Culture, Sports, Science, and Technology of Japan
Publisher
Springer Science and Business Media LLC
Reference50 articles.
1. Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87–108. https://doi.org/10.3322/caac.21262 (2015).
2. Rudin, C. M., Brambilla, E., Faivre-Finn, C. & Sage, J. Small-cell lung cancer. Nat. Rev. Dis. Primers 7, 3. https://doi.org/10.1038/s41572-020-00235-0 (2021).
3. Evans, W. K., Shepherd, F. A., Feld, R., Osoba, D. & Deboer, G. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. Lung Cancer 2, 1471–1477 (1985).
4. Dingemans, A. C. et al. Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up(☆). Ann. Oncol. 32, 839–853. https://doi.org/10.1016/j.annonc.2021.03.207 (2021).
5. Goldman, J. W. et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): Updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 22, 51–65. https://doi.org/10.1016/S1470-2045(20)30539-8 (2021).